Company News

 

September 5, 2002

Public Relations
Ono Pharmaceutical Co., Ltd.
Tel: +81-6-6222-5551
Fax: +81-6-6222-2875


Announcement of the Launch of Onoact® 50 for Injection, Japan's First Short-Acting Selective β1 Blocker
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka City, President: Kimiichiro Matsumoto) will launch Onoact® 50 for injection, the drug for intraoperative tachyarrhythmia (atrial fibrillation, atrial flutter and sinus tachycardia), on September 6, 2002.

During operation, various invasive procedures on a living body, such as endotracheal intubation, extubation, skin incision and other surgical procedures, facilitate the excessive discharge of catecholamine (noradrenaline, adrenalin, etc.) mainly from the sympathetic nerve, leading to an increase in heart rate, as well as tachyarrhythmia.

Especially in patients with ischemic heart disease and/or hypertension, even a slightly increased heart rate may constitute an additional burden on the heart, and induce ischemia at coronary artery etc. Therefore, the development of a drug that can be easily titrated for emergency treatment of intraoperative tachyarrhythmia has long been awaited.

Onoact® 50 for injection, which has been developed to fulfill these medical needs, improves tachyarrhythmia by selectively blocking β1 receptors located chiefly in the heart, and by inhibiting the action of catecholamine that raises the heart rate.

Onoact® 50 for injection can be used in emergency treatment of intraoperative tachyarrhythmia, because this fast-acting drug can be easily titrated for its very short half-life in blood (approx. 4 min). We expect that Onoact® 50 for injection will be widely used as an innovative frontline drug.


      Product Profile of Onoact® 50 for Injection


     Nonproprietary name : Landiolol hydrochloride

     Active ingredient : 50 mg landiolol hydrochloride per vial

     Indications : Emergency treatment for intraoperative tachyarrhythmia (atrial fibrillation, atrial flutter and sinus tachycardia)

     Dosage and administration : Landiolol hydrochloride is intravenously administered at 0.125 mg/kg/min for one minute, and at 0.04 mg/kg/min thereafter. The dosage should be appropriately adjusted between 0.01 and 0.04 mg/kg/min, based on the heart rate and blood pressure to be measured during the infusion.

     NHI drug price : 7,349 yen/vial

     Package : 5 vials or 10 vials of Onoact® 50 for injection

     Manufactured and distributed by : Ono Pharmaceutical Co., Ltd.